Bayer Ag · XETR:BAYN
Bayer — FY 2016 Earnings Presentation
8 slides from Bayer's earnings presentation, Feb 22, 2017
Slide 1: Investor Conference Call FY/Q4 2016 Results
Investor Conference Call FY/Q4 2016 Results February 22, 2017 / Werner Baumann, CEO Cautionary Statements Regarding Forward- Looking Information Certain statements contained in this communication may constitute “forward-looking statements.” Actual results could differ materially from those projected
Slide 2: FY 2016 – Highlights
FY 2016 – Highlights • Another record year for Bayer: Sales +3% (cpa), adj. EBITDA +10%, core EPS +7% • Substantial sales and earnings increases at Pharmaceuticals • Consumer Health grows with competition • Crop Science successful in a difficult market environment • Good progress with the acquisitio
Slide 3: Q4 2016 – Breakdown by Segment
Q4 2016 – Breakdown by Segment Sales EBITDA in € million; ∆% yoy, Fx & portfolio adj. before special items, in € million; ∆% yoy Pharma Consumer +7% Health +4% 2,179 +14% 1,539 1,609 1,916 4,275 1,217 +12% Covestro 1,085 2,997 +9% 3,490 372 -3% 385 Animal 351 +1% 2,404 329 Health 347 38 -7% +3% 41 C
Slide 4: FY 2016 – Earnings Targets More Than Achieved
FY 2016 – Earnings Targets More Than Achieved Sales ∆% yoy, Fx & portfolio adj., EBITDA before special items, continuing operations 2015 2016 Guidance 2016 ∆ 2016 Actual (original) Actual vs. 2015 low-single-digit % Sales €46.1bn increase to >€47bn €46.8bn +3% ✓ adj. EBITDA €10.3bn mid-single-digit
Slide 5: Consumer Health Grows with Competition
FY 2016 – Consumer Health Grows with Competition Sales Top Products EBITDA in € million; ∆% yoy, Fx & portfolio adj. 2016 sales in € million, ∆% yoy, Fx adj. before special items, in € million; ∆% yoy 6,076 1,001* +5% 1,456 6,037 +4% 1,411 -3% 605 -3% 416 +2% 362 +9% 2015 2016 Sum 2,384 +3% 2015 201
Slide 6: Animal Health With Strong Performance of Seresto
FY 2016 – Animal Health With Strong Performance of Seresto Sales Top Products EBITDA in € million; ∆% yoy, Fx & portfolio adj. 2016 sales in € million, ∆% yoy, Fx adj. before special items, in € million; ∆% yoy 1,490 1,523 +5% 535 0% 347 349 +1% 174 +55% 128 +7% 113 -5% 2015 Sum 950 +7% 2016 2015 20
Slide 7: FY 2017 – Guidance by Life Science Segment
FY 2017 – Guidance by Life Science Segment Sales * Adj. EBITDA * Mid-single-digit % increase to >€17bn High-sinlge-digit % increase Pharma Key growth products >€6bn Margin improvement Low- to mid-single-digit % increase to Consumer >€6bn, in line with expected market Low- to mid-single-digit % incre
Slide 8: Agreed Monsanto Acquisition – Status
Agreed Monsanto Acquisition – Status Regulatory • Good progress in obtaining antitrust approvals • Filings in roughly 2/3 of approx. 30 jurisdictions submitted • Regulatory filing in the European Union planned for Q2 2017 Financing • Successful placement of €4 billion mandatory convertible notes • F